Possibly, the integration in prospective studies of these biomarkers in peripheral blood with other already established biomarkers, such as TMB or PD-L1 expression in tumor tissue, will allow us to improve the selection of patients who will benefit most from ICIs in NSCLC and in other tumors. The gene discussed is CD274; the disease is non-small cell lung carcinoma.